CytomX Therapeutics (CTMX) Tops Q1 EPS by 21c

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of $0.27, $0.21 better than the analyst estimate of $0.06. Revenue for the quarter came in at $50.92 million versus the consensus estimate of $29.7 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AIG (AIG) on Watch Following Unconfirmed M&A Chatter
• Ouster (OUST) call put ratio 5.9 calls to 1 put with a focus on June 26 weekly calls